Octreotide Sun (Octreotide)

Octreotide mimics natural somatostatin by binding primarily to somatostatin receptor subtypes 2 and 5 on endocrine and neuroendocrine cells. This binding inhibits adenylate cyclase, lowers cyclic AMP, and suppresses the release of several hormones—including growth hormone, serotonin, and vasoactive intestinal peptide—thereby reducing the clinical manifestations of hormone‑driven diseases.

The dosage of Octreotide Sun is individualized based on the specific indication, patient weight, renal and hepatic function, and clinical response. A qualified prescriber determines the appropriate dose, route (intravenous or subcutaneous), and titration schedule. No fixed regimen is provided here; dosing information must be obtained from the prescribing physician.

Data on Octreotide use during pregnancy and lactation are limited. Animal studies have shown adverse effects, and human experience is insufficient to confirm safety. Consequently, Octreotide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus, and breastfeeding is generally not recommended unless the benefit outweighs the risk.

To order Octreotide Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assists with import documentation.

Octreotide and lanreotide are both long‑acting somatostatin analogs used for similar hormone‑excess conditions. Octreotide is available in short‑acting injectable forms for rapid titration, whereas lanreotide is typically administered as a deep‑subcutaneous depot with longer dosing intervals. Choice between them depends on clinical factors such as required dosing frequency, patient preference, and specific regulatory approvals in a given region.

Octreotide Sun must be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Once reconstituted, the product should be used within the time frame specified in the label and any unused portion discarded according to local regulations.

Octreotide Sun is supplied as a sterile powder for injection. After reconstitution with the appropriate diluent, it can be administered intravenously as a continuous infusion or subcutaneously as a bolus injection, depending on the clinical indication and prescriber’s instructions. Administration should be performed by trained healthcare personnel using aseptic technique.

Serious adverse events associated with Octreotide include acute pancreatitis, severe hyperglycemia that may require insulin therapy, gallstone formation or biliary colic, cardiac arrhythmias, hypotension, and anaphylactic reactions. Patients should be monitored for signs of abdominal pain, sudden changes in blood glucose, jaundice, or allergic symptoms, and medical attention should be sought promptly if they occur.

Octreotide is contraindicated in patients with known hypersensitivity to octreotide or any of its excipients. Caution is also advised in individuals with uncontrolled diabetes, severe hepatic impairment, or active gallbladder disease. Pregnant or breastfeeding women should only use the drug when the expected therapeutic benefit outweighs the potential risk to the fetus or infant.